Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa

This study was designed to explore the expression and the diagnostic value of vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pernicious placenta previa (PPP) combined placental accreta/increta. A total of 140 PPP patients were enrolled and divided into t...

Full description

Saved in:
Bibliographic Details
Main Authors: Na Wang, Dandan Shi, Na Li, Hongyuan Qi
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Annals of Medicine
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2021.1999492
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849340477805953024
author Na Wang
Dandan Shi
Na Li
Hongyuan Qi
author_facet Na Wang
Dandan Shi
Na Li
Hongyuan Qi
author_sort Na Wang
collection DOAJ
description This study was designed to explore the expression and the diagnostic value of vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pernicious placenta previa (PPP) combined placental accreta/increta. A total of 140 PPP patients were enrolled and divided into two groups: 56 patients with placenta accreta/increta (PA group), and 84 patients without placenta accreta/increta (non-PA group). In the same period, 46 pregnant women without PPP who had undergone caesarean section were selected as controls. The levels of VEGF and sFlt-1 in serum were detected by enzyme-linked immunosorbent assay. Diagnostic efficiency of VEGF and sFlt-1 in serum were evaluated by receiver operating characteristics curve. It was found that both VEGF and sFlt-1 had diagnostic value for PPP and placenta accreta/increta combined PPP. In addition, the levels of VEGF and sFlt-1 could be used to distinguish placenta accreta from placenta increta. VEGF was negatively correlated with sFlt-1 in PPP patients. In summary, the levels of VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between placenta accreta and increta.KEY POINTSThe levels of VEGF and sFlt-1 could be used to distinguish placenta accreta from placenta increta.VEGF is negatively correlated with sFlt-1 in PPP patients.The levels of VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between placenta accreta and increta.
format Article
id doaj-art-49c76eafdb5e4e7494170f22a8e5db55
institution Kabale University
issn 0785-3890
1365-2060
language English
publishDate 2021-01-01
publisher Taylor & Francis Group
record_format Article
series Annals of Medicine
spelling doaj-art-49c76eafdb5e4e7494170f22a8e5db552025-08-20T03:43:55ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602021-01-015312041204910.1080/07853890.2021.1999492Clinical value of serum VEGF and sFlt-1 in pernicious placenta previaNa Wang0Dandan Shi1Na Li2Hongyuan Qi3Obstetrics Department, Cangzhou Central Hospital, Cangzhou, ChinaObstetrics Department, Cangzhou Central Hospital, Cangzhou, ChinaObstetrics Department, Cangzhou Central Hospital, Cangzhou, ChinaObstetrics Department, Cangzhou Central Hospital, Cangzhou, ChinaThis study was designed to explore the expression and the diagnostic value of vascular endothelial growth factor (VEGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) in pernicious placenta previa (PPP) combined placental accreta/increta. A total of 140 PPP patients were enrolled and divided into two groups: 56 patients with placenta accreta/increta (PA group), and 84 patients without placenta accreta/increta (non-PA group). In the same period, 46 pregnant women without PPP who had undergone caesarean section were selected as controls. The levels of VEGF and sFlt-1 in serum were detected by enzyme-linked immunosorbent assay. Diagnostic efficiency of VEGF and sFlt-1 in serum were evaluated by receiver operating characteristics curve. It was found that both VEGF and sFlt-1 had diagnostic value for PPP and placenta accreta/increta combined PPP. In addition, the levels of VEGF and sFlt-1 could be used to distinguish placenta accreta from placenta increta. VEGF was negatively correlated with sFlt-1 in PPP patients. In summary, the levels of VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between placenta accreta and increta.KEY POINTSThe levels of VEGF and sFlt-1 could be used to distinguish placenta accreta from placenta increta.VEGF is negatively correlated with sFlt-1 in PPP patients.The levels of VEGF and sFlt-1 could be used as auxiliary indicators to diagnose PPP and distinguish between placenta accreta and increta.https://www.tandfonline.com/doi/10.1080/07853890.2021.1999492VEGFsFlt-1pernicious placenta previaplacenta accretaplacenta increta
spellingShingle Na Wang
Dandan Shi
Na Li
Hongyuan Qi
Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
Annals of Medicine
VEGF
sFlt-1
pernicious placenta previa
placenta accreta
placenta increta
title Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
title_full Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
title_fullStr Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
title_full_unstemmed Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
title_short Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa
title_sort clinical value of serum vegf and sflt 1 in pernicious placenta previa
topic VEGF
sFlt-1
pernicious placenta previa
placenta accreta
placenta increta
url https://www.tandfonline.com/doi/10.1080/07853890.2021.1999492
work_keys_str_mv AT nawang clinicalvalueofserumvegfandsflt1inperniciousplacentaprevia
AT dandanshi clinicalvalueofserumvegfandsflt1inperniciousplacentaprevia
AT nali clinicalvalueofserumvegfandsflt1inperniciousplacentaprevia
AT hongyuanqi clinicalvalueofserumvegfandsflt1inperniciousplacentaprevia